

Molecule to market: faster, at lower cost, with fewer surprises

Agnigent.AI is an AI-native pharma services company. We cut the delays, errors, regulatory deficiencies and market blind spots that slow generic medicines down and push their cost up, so you earn more on each medicine and patients pay less. AI agents do the groundwork, our domain experts check it, and your team makes the final call.

Waiting and delay

A year lost usually costs more than a failed study.

Defects and rework

Errors in supplier reports, repeated studies, deficiency letters, found late.

Information gaps

Crowded molecules, missed supplier warnings, dossiers idle in reachable markets.

Four agents to start. Portfolio leads.

Portfolio Agent

PILOTING NOW

Know what a molecule is worth before you commit. Risk-adjusted value from competitors, patents, price erosion and development risk; develop, license in or pass.

Try now on public data: Molecule assessment

Licensing Agent

DOSSIER SUMMARY: PILOTING SOON

Faster licensing deals, in more markets: a standard dossier summary partners can assess quickly, plus which countries each dossier can enter and who is already there.

Try now on public data: Market scan

Review Agent

FULL REVIEW: PILOTING SOON

A second expert check on suppliers' work (CROs, API makers, contract manufacturers), starting with BE studies, before it costs you a year.

Try now on public data: BE risk profile

Regulatory Agent

DOSSIER CHECK: PILOTING SOON

A second check before you file, starting with US labeling, and help with regulators' queries, so your team faces fewer review cycles.

Try now on public data: Guidance-change monitor

Coming next: IP, API sourcing, formulation, manufacturing, and tracking each molecule's value after launch.

How we work

1. **Find** where time and money are lost, using lean methods.
2. **Understand** why, with pharma experts, adding market risks.
3. **Size** each item against the medicine's return and cost; rank what to fix first.
4. **Fix and track:** agents do the groundwork, experts check, your team decides.

One problem. One month. Measured.

- You choose one problem: severe, measurable, and needing no more data than you would share with a supplier under an NDA.
- Week 1, a baseline; weeks 2–3, agents run on real cases with your team; week 4, the result measured and reviewed with management.
- Delivered as a service, like a CRO: no licences, installation or training on your side.
- Pay for results: a share of the measured saving, with a cap agreed up front.

Your data is used only for your work. It is never shared with, or used for, another customer. Today we work on public data plus figures you choose to share; confidential documents only once they can be held on dedicated, access-controlled infrastructure. Our findings support your team's review; your quality system stays the system of record. We start with the US, the EU and the UK.

Suneel Regulla, Founder & CEO, Hyderabad

Former Chairman of Accutest Research Laboratories (a clinical research organisation); founder of Hansa Equity Partners (life-sciences investing in India); nine years in Nordic mid-market private equity at FSN Capital.

Book a 30-minute conversation:

calendar.app.google/v2fvUGZFL2CQ1rgq7

Domain expert? Join the panel: www.agnigent.ai/#experts